Regulatory & Submissions · PMA Support
PMA Submission Support
The short answer
A PMA is reviewed alongside a pre-approval inspection of the manufacturing site, which means the manufacturing section is not paperwork — it is a description of a facility that will be examined. We build the manufacturing, quality system and validation content of PMA submissions and prepare the site to be consistent with what was filed.
01
Why this matters
- The PMA manufacturing section commits your site to specific processes, controls and specifications. Every one of those becomes an inspection reference point.
- Design control and risk management records are examined in depth for Class III devices, and gaps found here are expensive at this stage.
- Process validation for a PMA device is expected to be complete and defensible, not planned.
02
Applicable regulations and standards
- 21 CFR Part 814
- Premarket approval application content, amendments and supplements.
- 21 CFR Part 820 / QMSR
- Quality system requirements evaluated during the pre-approval inspection.
- ISO 14971
- Risk management file expected to support the benefit-risk discussion.
- 21 CFR Part 11
- Electronic records and signatures supporting design, production and clinical data.
03
What our consultants actually do
- Draft the manufacturing, facilities, process control and quality system sections from real site documentation
- Assess process, cleaning, sterilization and software validation completeness against PMA expectations
- Reconcile the design history file, risk management file and technical documentation
- Run a readiness assessment for the PMA pre-approval inspection using former FDA investigators
- Support PMA supplements and annual reports as the process or supplier base changes
- Prepare the site team for technical questions on validation rationale and control strategy
04
Across the product lifecycle
01 / DEVELOP
Design inputs and risk analysis structured for Class III scrutiny.
02 / SCALE
Commercial-scale process defined before the manufacturing section is written.
03 / TRANSFER
Design transfer and supplier controls documented.
04 / VALIDATE
Full validation package: process, sterilization, packaging, software.
05 / MANUFACTURE
Production matching the filed description exactly.
06 / MAINTAIN
PMA supplements triggered correctly by change control.
05
Problems we are usually called about
- Manufacturing section written by regulatory staff without reconciliation to the DMR
- Validation reports that state conclusions without documenting the acceptance rationale
- Supplier controls described in the submission that the site does not actually perform
- Risk management file not updated after design changes late in development
- No mapping between filed commitments and the procedures that implement them
06
Typical deliverables
- Drafted PMA manufacturing and quality system sections
- Validation completeness assessment and remediation plan
- DHF / risk file reconciliation report
- Pre-approval inspection readiness report with prioritized actions
- Change control mapping for future PMA supplements
07
Frequently asked
- How early should manufacturing be involved in a PMA?
- Before the validation strategy is fixed. The manufacturing section describes a validated process; if validation is designed without reference to what will be filed, the two rarely line up and the correction happens under review pressure.
- Do you support the pre-approval inspection itself?
- We prepare the site — records, narratives, subject matter expert coaching and gap remediation. For dedicated inspection-day management and 483 response work, FDAInspections.com is the ecosystem resource built for that.
- What triggers a PMA supplement?
- Changes affecting safety or effectiveness — design, manufacturing process, facility, sterilization, labeling or specifications. The practical work is building a change control step that classifies the change and records the rationale.
08
References
More for regulatory & submissions
Technical, manufacturing and quality support for US FDA submissions — written by people who have reviewed and inspected against them.
- 510(k) SupportA 510(k) is an argument for substantial equivalence, supported by evidence your quality system has to be able to produce on demand.
- De Novo SupportA De Novo asks FDA to create a classification, which means the submission has to propose the controls that will make the device type safe and effective.
- IND SupportFor an IND, the section that most often holds up a program is CMC.
- NDA SupportBy NDA, the manufacturing story has to be complete: a justified control strategy, validated process, qualified methods and a site that can demonstrate all of it during a pre-approval inspection.
- ANDA SupportGeneric applications are decided as much on manufacturing quality and data credibility as on bioequivalence.
- BLA SupportFor a biologic, the process is a substantial part of the product.
- IDE SupportAn IDE requires a description of how the investigational device is made and controlled, and design controls apply even though the device is not yet cleared.
Start a project
Tell us what you're working on.
Describe the product, the process or the problem. We will tell you honestly whether we are the right people to help, and who should be on the team if we are.